Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client

Journal of Molecular Endocrinology

Volumn 49, Issue 2, 2012, Pages 57-68

  Trotta, Andrew P ^a   Need, Eleanor F ^a   Butler, Lisa M ^a   Selth, Luke A ^a   O'Loughlin, Melissa A ^a   Coetzee, Gerhard A ^b   Tilley, Wayne D ^a   Buchanan, Grant ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANDROGEN RECEPTOR; ANDROSTANOLONE; SMALL GLUTAMINE RICH TETRATRICOPEPTIDE REPEAT CONTAINING ALPHA; TETRATRICOPEPTIDE REPEAT PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DIMERIZATION; GENE LOCUS; GENETIC CONSERVATION; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CARRIER PROTEINS; CERCOPITHECUS AETHIOPS; CONSERVED SEQUENCE; COS CELLS; DIHYDROTESTOSTERONE; GENES, REPORTER; LIGANDS; MOLECULAR CHAPERONES; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; TRANSCRIPTION FACTORS;

EID: 84866344619     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-11-0152     Document Type: Article

References (49)

1. Angeletti PC, Walker D & Panganiban AT 2002 Small glutamine-rich protein/viral protein U-binding protein is a novel cochaperone that affects heat shock protein 70 activity. Cell Stress & Chaperones 7 258-268. (doi:10.1379/1466-1268(2002)007!0258:SGRPVPO2.0. CO;2)
2. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E et al. 2008 Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology 26 4563-4571. (doi:10.1200/JCO.2007.15.9749)
3. Attard G, Richards J & de Bono JS 2011 Targeting the androgen receptor signaling pathway in metastatic prostate cancer. Clinical Cancer Research 17 1649-1657. (doi:10.1158/1078-0432)
4. Barent RL, Nair SC, Carr DC, Ruan Y, Rimerman RA, Fulton J, Zhang Y & Smith DF 1998 Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. Molecular Endocrinology 12 342-354. (doi:10.1210/me.12.3.342)
5. Blom N, Gammeltoft S & Brunak S 1999 Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. Journal of Molecular Biology 294 1351-1362. (doi:10.1006/jmbi.1999.3310)
6. Bryne JC, Valen E, Tang MH, Marstrand T, Winther O, da Piedade I, Krogh A, Lenhard B & Sandelin A 2008 JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update. Nucleic Acids Research 36 D102-D106. (doi:10.1093/nar/gkm955)
7. Buchanan G, Craft PS, YangM, Cheong A, Prescott J, Jia L, Coetzee GA & Tilley WD 2004a PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. Prostate 60 352-366. (doi:10.1002/pros.20079)
8. Buchanan G, Yang M, Cheong A, Harris JM, Irvine RA, Lambert PF, Moore NL, Raynor M, Neufing PJ, Coetzee GA et al. 2004b Structural and functional consequences of glutamine tract variation in the androgen receptor. Human Molecular Genetics 13 1677-1692. (doi:10.1093/hmg/ddh181)
9. Buchanan G, Ricciardelli C, Harris JM, Prescott J, Yu ZC, Jia L, Butler LM, Marshall VR, Scher HI, Gerald WL et al. 2007 Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha. Cancer Research 67 10087-10096. (doi:10.1158/0008-5472.CAN-07-1646)
10. Butler LM, Centenera MM, Neufing PJ, Buchanan G, Choong CS, Ricciardelli C, Saint K, Lee M, Ochnik A, Yang M et al. 2006 Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Molecular Endocrinology 20 1009-1024. (doi:10.1210/me.2004-0401)
11. Cheung-Flynn J, Prapapanich V, Cox MB, Riggs DL, Suarez-Quian C & Smith DF 2005 Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Molecular Endocrinology 19 1654-1666. (doi:10.1210/me.2005-0071)
12. Chmelar R, Buchanan G, Need EF, Tilley W & Greenberg NM 2007 Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. International Journal of Cancer 120 719-733. (doi:10.1002/ijc.22365)
13. Cziepluch C, Kordes E, Poirey R, Grewenig A, Rommelaere J & Jauniaux JC 1998 Identification of a novel cellular TPR-containing protein, SGT, that interacts with the nonstructural protein NS1 of parvovirus H-1. Journal of Virology 72 4149-4156.
14. Cziepluch C, Lampel S, Grewenig A, Grund C, Lichter P & Rommelaere J 2000 H-1 parvovirus-associated replication bodies: a distinct virus-induced nuclear structure. Journal of Virology 74 4807-4815. (doi:10.1128/JVI.74.10.4807-4815.2000)
15. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C et al. 2010 Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of Clinical Oncology 28 1496-1501. (doi:10.1200/JCO.2009. 25.9259)
16. Davies TH, Ning YM & Sanchez ER 2002 A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. Journal of Biological Chemistry 277 4597-4600. (doi:10.1074/jbc.C100531200)
17. Denny WB, Valentine DL, Reynolds PD, Smith DF & Scammell JG 2000 Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 141 4107-4113. (doi:10.1210/en.141.11.4107)
18. Feldman BJ & Feldman D 2001 The development of androgenindependent prostate cancer. Nature Reviews. Cancer 1 34-45. (doi:10.1038/35094009)
19. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J & Jenster G 2006 Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Research 66 5012-5020. (doi:10.1158/0008-5472. CAN-05-3082)
20. Ji H, Jiang H, Ma W, Johnson DS, Myers RM & Wong WH 2008 An integrated software system for analyzing ChIP-chip and ChIP-seq data. Nature Biotechnology 26 1293-1300. (doi:10.1038/nbt.1505)
21. Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, Chen T, Buchanan G, Frenkel B & Coetzee GA 2008 Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS ONE 3 e3645. (doi:10.1371/journal.pone.0003645)
22. Katzman S, Barrett C, Thiltgen G, Karchin R & Karplus K 2008 PREDICT-2ND: a tool for generalized protein local structure prediction. Bioinformatics 24 2453-2459. (doi:10.1093/bioinformatics/btn438)
23. Knudsen KE & Penning TM 2010 Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends in Endocrinology and Metabolism 21 315-324. (doi:10.1016/j.tem.2010. 01.002)
24. Liou ST &Wang C 2005 Small glutamine-rich tetratricopeptide repeatcontaining protein is composed of three structural units with distinct functions. Archives of Biochemistry and Biophysics 435 253-263. (doi:10.1016/j.abb.2004.12.020)
25. Liu FH, Wu SJ, Hu SM, Hsiao CD & Wang C 1999 Specific interaction of the 70-kDa heat shock cognate protein with the tetratricopeptide repeats. Journal of Biological Chemistry 274 34425-34432. (doi:10.1074/jbc.274.48.34425)
26. Marcelli M, StenoienDL, SzafranAT, Simeoni S, Agoulnik IU, WeigelNL, Moran T, Mikic I, Price JH & Mancini MA 2006 Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. Journal of Cellular Biochemistry 98 770-788. (doi:10.1002/jcb.20593)
27. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD & Nelson PS 2008 Maintenance of intratumoral androgens inmetastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research 68 4447-4454. (doi:10.1158/0008-5472.CAN-08-0249)
28. NeedEF, ScherHI, Peters AA, MooreNL, CheongA, RyanCJ, Wittert GA, Marshall VR, Tilley WD & Buchanan G 2009 A novel androgen receptoramino terminal region reveals two classes ofamino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin. Endocrinology 150 2674-2682. (doi:10.1210/en.2008-1181)
29. Periyasamy S, Warrier M, Tillekeratne MP, Shou W & Sanchez ER 2007 The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and-independent mechanisms. Endocrinology 148 4716-4726. (doi:10.1210/en.2007-0145)
30. Periyasamy S, Hinds T Jr, Shemshedini L, Shou W & Sanchez ER 2010 FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene 29 1691-1701. (doi:10.1038/onc.2009.458)
31. Pratt WB & Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrine Reviews 18 306-360. (doi:10.1210/er.18.3.306)
32. Schantl JA, RozaM, De Jong AP & Strous GJ 2003 Small glutamine-rich tetratricopeptide repeat-containing protein (SGT) interacts with the ubiquitin-dependent endocytosis (UbE) motif of the growth hormone receptor. Biochemical Journal 373 855-863. (doi:10.1042/BJ20021591)
33. Scher HI & Sawyers CL 2005 Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgenreceptor signaling axis. Journal of Clinical Oncology 23 8253-8261. (doi:10.1200/JCO.2005.03.4777)
34. Scher HI, Buchanan G, Gerald W, Butler LM & Tilley WD 2004 Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer 11 459-476. (doi:10.1677/erc.1.00525)
35. Schulke JP, Wochnik GM, Lang-Rollin I, Gassen NC, Knapp RT, Berning B, Yassouridis A & Rein T 2010 Differential impact of tetratricopeptide repeat proteins on the steroid hormone receptors. PLoS ONE 5 e11717. (doi:10.1371/journal.pone. 0011717)
36. Smith DF 2004 Tetratricopeptide repeat cochaperones in steroid receptor complexes. Cell Stress & Chaperones 9 109-121. (doi:10.1379/CSC-31.1)
37. Sun K, Montana V, Chellappa K, Brelivet Y, Moras D, Maeda Y, Parpura V, Paschal BM & Sladek FM 2007 Phosphorylation of a conserved serine in the deoxyribonucleic acid binding domain of nuclear receptors alters intracellular localization. Molecular Endocrinology 21 1297-1311. (doi:10.1210/me.2006-0300)
38. Thomas M, Harrell JM, Morishima Y, Peng HM, Pratt WB & Lieberman AP 2006 Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction. Human Molecular Genetics 15 1876-1883. (doi:10.1093/hmg/ddl110)
39. Tobaben S, Varoqueaux F, Brose N, Stahl B & Meyer G 2003 A brain-specific isoform of small glutamine-rich tetratricopeptide repeat-containing protein binds to Hsc70 and the cysteine string protein. Journal of Biological Chemistry 278 38376-38383. (doi:10.1074/jbc.M301558200)
40. Vacic V, Uversky VN, Dunker AK & Lonardi S 2007 Composition Profiler: a tool for discovery and visualization of amino acid composition differences. BMC Bioinformatics 8 211. (doi:10.1186/1471-2105-8-211)
41. Wang H, Zhang Q & Zhu D 2003 hSGT interacts with the N-terminal region of myostatin. Biochemical and Biophysical Research Communications 311 877-883. (doi:10.1016/j.bbrc.2003.10.080)
42. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M et al. 2009 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138 245-256. (doi:10.1016/j.cell.2009.04.056)
43. Wilson EM & French FS 1976 Binding properties of androgen receptors. Evidence for identical receptors in rat testis, epididymis, and prostate. Journal of Biological Chemistry 251 5620-5629.
44. Winnefeld M, Rommelaere J & Cziepluch C 2004 The human small glutamine-rich TPR-containing protein is required for progress through cell division. Experimental Cell Research 293 43-57. (doi:10.1016/j.yexcr.2003.09.028)
45. Winnefeld M, Grewenig A, Schnolzer M, Spring H, Knoch TA, Gan EC, Rommelaere J & Cziepluch C 2006 Human SGT interacts with Bag-6/Bat-3/Scythe and cells with reduced levels of either protein display persistence of few misaligned chromosomes and mitotic arrest. Experimental Cell Research 312 2500-2514. (doi:10.1016/j.yexcr.2006.04.020)
46. Yin H, Wang H, Zong H, Chen X, Wang Y, Yun X, Wu Y, Wang J & Gu J 2006 SGT, a Hsp90beta binding partner, is accumulated in the nucleus during cell apoptosis. Biochemical and Biophysical Research Communications 343 1153-1158. (doi:10.1016/j.bbrc.2006.03.090)
47. Yong W, Yang Z, Periyasamy S, Chen H, Yucel S, Li W, Lin LY, Wolf IM, Cohn MJ, Baskin LS et al. 2007 Essential role for co-chaperone Fkbp52 but not Fkbp51 in androgen receptor-mediated signaling and physiology. Journal of Biological Chemistry 282 5026-5036. (doi:10.1074/jbc.M609360200)
48. Zhang L, Johnson M, Le KH, Sato M, Ilagan R, Iyer M, Gambhir SS, Wu L & Carey M 2003 Interrogating androgen receptor function in recurrent prostate cancer. Cancer Research 63 4552-4560.
49. Ziegler EC & Ghosh S 2005 Regulating inducible transcription through controlled localization. Science's STKE 2005 re6. (doi:10.1126/stke.2842005re6)